Aurobindo Pharma Share Price Declines After US FDA Issues 10 Observations For Telangana Facility
Aurobindo Pharma Ltd.'s share price fell over 4% on Monday after the US Food and Drug Administrator issued 10 observations following the inspection at the company's facility in Telangana.
The inspection was conducted between Sept. 23 and Sept. 27, the Hyderabad-based bulk and generic drugmaker said in an exchange filing.
"The United States Food and Drug Administration (USFDA) inspected Unit-II, an API manufacturing facility, of Apitoria Pharma Private Ltd., a wholly owned subsidiary of the company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana," the company said in the filing.
"The inspection closed with 10 observations," it said. The observations are "procedural in nature" and will be responded to within the stipulated time, it said.
Notably, Aurobindo Pharma was also in the news last week after UBS initiated coverage on the stock with a "sell" rating. The brokerage issued a target price of Rs 1,333, which projected a potential downside of 12% against the then market price.
In the quarter ended June 2024, Aurobindo Pharma had logged a 61% year-on-year jump in net profit to Rs 918 crore. The company's revenue grew 10% to Rs 7,567 crore.

Shares of Aurobindo Pharma fell 4.49% to a low of Rs 1,443.5 apiece on the NSE. The stock later pared losses to trade 2.21% lower at Rs 1,447.90 apiece, compared with a 1.2% decline in the benchmark Nifty 50 as of 1:49 p.m.
The stock has risen 36.3% so far this year and 61.6% over the last 12 months. The stock's total traded volume so far in the day stood at 0.88 times its 30-day average. The relative strength index was at 70.1.
Twenty out of the 29 analysts tracking the company have a "buy" rating on the stock, five suggest a "hold" and four have a "sell", according to Bloomberg data. The average of 12-month analyst price targets implies a potential upside of 6.6%.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.